Standard versus Reduced-Dose Valganciclovir CMV Prophylaxis in High-Risk Liver Transplant Recipients

被引：0
|
作者：
Dann, J. [1 ]
Geyston, J. [1 ]
Majmundar, D. [1 ]
Haywood, S. [1 ]
Shoemaker, C. [1 ]
Pelletier, S. [1 ]
Wentworth, B. [1 ]
机构：
[1] UVA Univ Virginia Hlth, Charlottesville, VA USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2023年 / 23卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
120
引用
收藏
页码：S395 / S395
页数：1
相关论文
共 50 条
  • [31] FLUCONAZOLE PROPHYLAXIS FOR HIGH-RISK LIVER-TRANSPLANT RECIPIENTS
    KUNG, N
    FISHER, N
    GUNSON, B
    HASTINGS, M
    MUTIMER, D
    LANCET, 1995, 345 (8959): : 1234 - 1235
  • [32] Prophylactic antiviral therapy in CMV high-risk liver transplant recipients
    Rabkin, JM
    Rosen, HR
    Corless, CL
    Orloff, SL
    Olyaei, AJ
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) : 1811 - 1812
  • [33] Efficacy and Safety of Delayed, Low-Dose Valganciclovir in High-Risk Cytomegalovirus Liver Transplant Recipients.
    Anders, S.
    Freeman, A.
    Hutchinson, L.
    Kaszubski, U.
    Janusek, M.
    Hooter, A.
    Raymond, D.
    Nguyen, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 1075 - 1075
  • [34] CMV prophylaxis with valganciclovir in CMV-seropositive kidney- and liver-transplant recipients:: A pilot study
    Weclawiack, Hugo
    Kamar, Nassim
    Mengelle, Catherine
    Guitard, Joelle
    Ribes, David
    Lavayssiere, Laurence
    Esposito, Laure
    Cointault, Olivier
    Durand, Dominique
    Rostaing, Lionel
    TRANSPLANT INTERNATIONAL, 2007, 20 : 206 - 206
  • [35] Utilization of a CMV T Cell Immunity Panel in Directing Duration of Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients
    Ray, A.
    Garner, B.
    Klein, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S793 - S793
  • [36] Increased incidence of late-onset CW disease in high-risk liver transplant recipients receiving valganciclovir prophylaxis
    Shiley, Kevin T.
    Gasink, Leanne B.
    Barton, Todd D.
    Pfeiffenberger, Patrice
    Olthoff, Kim M.
    Blumberg, Emily A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 564 - 564
  • [37] Is CMV Prophylaxis Necessary in CMV Low-Risk Liver Transplant Recipients?
    Fleming, J. N.
    Bowman, L.
    Truscott, C.
    Pilch, N.
    Taber, D.
    Pote, L.
    Powderly, A.
    Mathur, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 474 - 474
  • [38] The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
    Humar, A.
    Lebranchu, Y.
    Vincenti, F.
    Blumberg, E. A.
    Punch, J. D.
    Limaye, A. P.
    Abramowicz, D.
    Jardine, A. G.
    Voulgari, A. T.
    Ives, J.
    Hauser, I. A.
    Peeters, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (05) : 1228 - 1237
  • [39] Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients
    Dupuis, R.
    Harris, M.
    Gillis, K.
    Gerber, D.
    Fair, J.
    Watson, R.
    Koslowski, T.
    Andreoni, K.
    TRANSPLANTATION PROCEEDINGS, 2007, 39 (10) : 3266 - 3270
  • [40] Question of using valganciclovir for cytomegalovirus (CMV) infection prophylaxis in post-liver transplant recipients
    Jain, Ashok
    Mohanka, Ravi
    Orloff, Mark
    Abt, Peter
    Ryan, Charlotte
    Bozorgzadeh, Adel
    LIVER TRANSPLANTATION, 2006, 12 (06) : 1020 - 1021
12345